Scarica l'app Stockscreener
0.6105
1.72%
0.0103
Dopo l'orario di chiusura:
.60
-0.0105
-1.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe
VistaGen appoints Nick Tressler as CFO - MSN
Vistagen Therapeutics Inc (MEX:VTGN) Competitors 2026 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-04-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse
Who's Buying or Selling Vistagen Therapeutics Inc (MEX:VTGN) Stock Today? - GuruFocus
Vistagen Therapeutics Inc Stock Intrinsic Values | MEX:VTGN - GuruFocus
Vistagen Therapeutics Inc Stock Historical Valuations - GuruFocus
Vistagen Therapeutics Inc Stock Warning Signs - GuruFocus
Vistagen Therapeutics Inc (MEX:VTGN) Stock Price, Trades & News - GuruFocus
Q3 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q2 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Vistagen Therapeutics Inc (MEX:VTGN) Stock Earnings Transcripts - GuruFocus
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review
Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies - MSN
Vistagen Therapeutics (VTGN) Stock: Buy Decision Breakdown | Q1 2026: Earnings Beat EstimatesCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
VistaGen Therapeutics, Inc. (VTGN) reports Q3 loss, lags revenue estimates - MSN
Breakthrough for Vistagen (VTGN) as FDA Approves Phase 2 Development - GuruFocus
Hot flash nasal spray moves ahead after FDA allows U.S. study - Stock Titan
Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - Yahoo Finance
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - WFXG
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - ADVFN
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeuti - The National Law Review
2026-04-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Therapeutics Inc (MEX:VTGN) Stock Price & 30 Year Financial Data - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Vistagen Therapeutics, Inc. Files Form 8-K with SEC – Company Information, Address, and Stock Details (April 2026) - Minichart
Vistagen Therapeutics grants stock options to executives and employees By Investing.com - Investing.com Australia
Vistagen Therapeutics grants stock options to executives and employees - Investing.com
VistaGen Therapeutics Grants Broad Employee Retention Stock Options - TipRanks
Vistagen awards stock options to CEO Shawn K. Singh and CFO Nick B. Tressler - TradingView
[8-K] Vistagen Therapeutics, Inc. Reports Material Event - Stock Titan
Institution Moves: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn
2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse
Trading Recap: What is the next catalyst for Vistagen Therapeutics IncInsider Selling & Low Volatility Stock Suggestions - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Vistagen Therapeutics Inc a potential multi bagger2026 Reactions & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Hedge Fund Bets: Can Vistagen Therapeutics Inc sustain earnings growthMarket Volume Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Quarterly Risk: Can Vistagen Therapeutics Inc sustain earnings growth2026 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen (VTGN) CFO awarded 75,000 stock options at $0.5358 - Stock Titan
Vistagen (NASDAQ: VTGN) CEO receives 75K stock options grant - Stock Titan
Vistagen (VTGN) awards stock options to its Chief Legal Officer - Stock Titan
Bull Run: Should value investors consider Vistagen Therapeutics Inc2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):